{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:06:54Z","timestamp":1772791614113,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04029-3","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:08:42Z","timestamp":1772780922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of optical coherence tomography biomarkers on treatment outcomes in patients with diabetic macular edema"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8796-1143","authenticated-orcid":false,"given":"Ozgu Canbolat","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1340-543X","authenticated-orcid":false,"given":"Zeliha","family":"Yazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8797-9634","authenticated-orcid":false,"given":"Mehmet","family":"Onen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2160-2126","authenticated-orcid":false,"given":"Muzaffer","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"4029_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/aos.13210","volume":"95","author":"A Campos","year":"2017","unstructured":"Campos A, Campos EJ, Martins J, Ambr\u00f3sio AF, Silva R (2017) Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema. Acta Ophthalmol 95:446\u2013459","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"4029_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/medicina59030629","volume":"59","author":"YC Chang","year":"2023","unstructured":"Chang YC, Huang YT, Hsu AY, Meng PP, Lin CJ, Lai CT, Hsia NY, Chen HS, Tien PT, Lin JM, Chen WL, Tsai YY (2023) Optical coherence tomography biomarkers in predicting treatment outcomes of diabetic macular edema after ranibizumab injections. Medicina (Kaunas) 59(3):629. https:\/\/doi.org\/10.3390\/medicina59030629","journal-title":"Medicina (Kaunas)"},{"issue":"3","key":"4029_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/APO.0000000000000468","volume":"11","author":"VWK Hui","year":"2022","unstructured":"Hui VWK, Szeto SKH, Tang F, Yang D, Chen H, Lai TYY, Rong A, Zhang S, Zhao P, Ruamviboonsuk P, Lai CC, Chang A, Das T, Ohji M, Huang SS, Sivaprasad S, Wong TY, Lam DSC, Cheung CY (2022) Optical coherence tomography classification systems for diabetic macular edema and their associations with visual outcome and treatment responses - an updated review. Asia Pac J Ophthalmol (Phila) 11(3):247\u2013257. https:\/\/doi.org\/10.1097\/APO.0000000000000468","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"4029_CR4","doi-asserted-by":"publisher","first-page":"104042","DOI":"10.1016\/j.pdpdt.2024.104042","volume":"46","author":"P Viggiano","year":"2024","unstructured":"Viggiano P, Vujosevic S, Palumbo F, Grassi MO, Boscia G, Borrelli E, Reibaldi M, Sborgia L, Molfetta T, Evangelista F, Alessio G, Boscia F (2024) Optical coherence tomography biomarkers indicating visual enhancement in diabetic macular edema resolved through anti-VEGF therapy: OCT biomarkers in resolved DME. Photodiagnosis Photodyn Ther 46:104042. https:\/\/doi.org\/10.1016\/j.pdpdt.2024.104042","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"10","key":"4029_CR5","doi-asserted-by":"publisher","first-page":"e0206482","DOI":"10.1371\/journal.pone.0206482","volume":"13","author":"V Schreur","year":"2018","unstructured":"Schreur V, Altay L, van Asten F, Groenewoud JMM, Fauser S, Klevering BJ, Hoyng CB, de Jong EK (2018) Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema. PLoS ONE 13(10):e0206482. https:\/\/doi.org\/10.1371\/journal.pone.0206482","journal-title":"PLoS ONE"},{"issue":"6","key":"4029_CR6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/IAE.0000000000001687","volume":"38","author":"AR Santos","year":"2018","unstructured":"Santos AR, Costa M\u00c2, Schwartz C, Alves D, Figueira J, Silva R, Cunha-Vaz JG (2018) Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema: the CHARTRES study. Retina 38(6):1110\u20131119. https:\/\/doi.org\/10.1097\/IAE.0000000000001687","journal-title":"Retina"},{"issue":"2","key":"4029_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ophtha.2017.08.031","volume":"125","author":"D Zur","year":"2018","unstructured":"Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A, International Retina Group (2018) OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology 125(2):267\u2013275. https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.031","journal-title":"Ophthalmology"},{"issue":"5","key":"4029_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/aos.13294","volume":"95","author":"S Vujosevic","year":"2017","unstructured":"Vujosevic S, Torresin T, Bini S, Convento E, Pilotto E, Parrozzani R, Midena E (2017) Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol 95(5):464\u2013471. https:\/\/doi.org\/10.1111\/aos.13294","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"4029_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","volume":"132","author":"JK Sun","year":"2014","unstructured":"Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, Aiello LP (2014) Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol 132(11):1309\u20131316. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2350","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"4029_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00347-004-1054-9","volume":"101","author":"U Schaudig","year":"2004","unstructured":"Schaudig U, Scholz F, Lerche RC, Richard G (2004) [Optical coherence tomography for macular edema. Classification, quantitative assessment, and rational usage in the clinical practice]. Ophthalmologe 101(8):785\u2013793. https:\/\/doi.org\/10.1007\/s00347-004-1054-9","journal-title":"Ophthalmologe"},{"key":"4029_CR11","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1111\/aos.13935","volume":"97","author":"V Bonfiglio","year":"2019","unstructured":"Bonfiglio V, Reibaldi M, Pizzo A, Russo A, Macchi I, Faro G, Avitabile T, Longo A (2019) Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers. Acta Ophthalmol 97:e540\u2013e544","journal-title":"Acta Ophthalmol"},{"key":"4029_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/diagnostics10060413","volume":"10","author":"I Ceravolo","year":"2020","unstructured":"Ceravolo I, Oliverio GW, Alibrandi A, Bhatti A, Trombetta L, Rejdak R, Toro MD, Trombetta CJ (2020) The application of structural retinal biomarkers to evaluate the effect of intravitreal Ranibizumab and Dexamethasone intravitreal implant on treatment of diabetic macular edema. Diagnostics Basel 10:413","journal-title":"Diagnostics Basel"},{"key":"4029_CR13","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1097\/IAE.0000000000000228","volume":"34","author":"MR Munk","year":"2014","unstructured":"Munk MR, Sacu S, Huf W, Sulzbacher F, Mitterm\u00fcller TJ, Eibenberger K, Rezar S, Bolz M, Kiss CG, Simader C et al (2014) Differential diagnosis of macular edema of different pathophysiologic origins by spectral domain optical coherence tomography. Retina 34:2218\u20132232","journal-title":"Retina"},{"key":"4029_CR14","doi-asserted-by":"publisher","first-page":"5958","DOI":"10.1167\/iovs.17-22725","volume":"58","author":"HS Hwang","year":"2017","unstructured":"Hwang HS, Chae JB, Kim JY, Kim DY (2017) Association between hyperreflective dots on spectral-domain optical coherence tomography in macular edema and response to treatment. Invest Ophthalmol Vis Sci 58:5958\u20135967","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4029_CR15","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2008.12.039","volume":"116","author":"M Bolz","year":"2009","unstructured":"Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C (2009) Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 116:914\u2013920","journal-title":"Ophthalmology"},{"issue":"4","key":"4029_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/iae.0000000000001626","volume":"38","author":"W Fickweiler","year":"2018","unstructured":"Fickweiler W, Schauwvlieghe AME, Schlingemann RO, Maria Hooymans JM, Los LI, Verbraak FD (2018) Predictive value of optical coherence tomographic features in the bevacizumab and ranibizumab in patients with diabetic macular edema (BRDME) study. Retina 38(4):812\u2013819. https:\/\/doi.org\/10.1097\/iae.0000000000001626","journal-title":"Retina"},{"issue":"2","key":"4029_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000497406","volume":"62","author":"P Massin","year":"2019","unstructured":"Massin P, Creuzot-Garcher C, Kodjikian L et al (2019) Real-world outcomes with ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema: 12-Month results from the 36-month BOREAL-DME study. Ophthalmic Res 62(2):101\u2013110. https:\/\/doi.org\/10.1159\/000497406","journal-title":"Ophthalmic Res"},{"key":"4029_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","volume":"172","author":"VH Gonzalez","year":"2016","unstructured":"Gonzalez VH, Campbell J, Holekamp NM et al (2016) Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: Analysis of Protocol I data. Am J Ophthalmol 172:72\u201379. https:\/\/doi.org\/10.1016\/j.ajo.2016.09.012","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"4029_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","volume":"100","author":"C Pr\u00fcnte","year":"2016","unstructured":"Pr\u00fcnte C, Fajnkuchen F, Mahmood S et al (2016) Ranibizumab 0.5\u2005mg treat-and-extend regimen for diabetic macular oedema: The RETAIN study. Br J Ophthalmol 100(6):787\u2013795. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307249","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"4029_CR20","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.ophtha.2015.08.006","volume":"122","author":"DS Boyer","year":"2015","unstructured":"Boyer DS, Nguyen QD, Brown DM, Basu K, Ehrlich JS (2015) Outcomes with as-needed ranibizumab after initial monthly therapy: Long-term outcomes of the Phase III RIDE and RISE trials. Ophthalmology 122(12):2504\u201313.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2015.08.006","journal-title":"Ophthalmology"},{"issue":"4","key":"4029_CR21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789\u2013801. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.039","journal-title":"Ophthalmology"},{"key":"4029_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40662-018-0119-9","volume":"5","author":"A Campos","year":"2018","unstructured":"Campos A, Campos EJ, do Carmo A et al (2018) Evaluation of markers of outcome in real-world treatment of diabetic macular edema. Eye and Vision 5:27. https:\/\/doi.org\/10.1186\/s40662-018-0119-9","journal-title":"Eye and Vision"},{"issue":"2","key":"4029_CR23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1167\/iovs.16-20855","volume":"58","author":"A Giocanti-Aur\u00e9gan","year":"2017","unstructured":"Giocanti-Aur\u00e9gan A, Hrarat L, Qu LM et al (2017) Functional and anatomical outcomes in patients with serous retinal detachment in diabetic macular edema treated with ranibizumab. Invest Ophthalmol Vis Sci 58(2):797\u2013800. https:\/\/doi.org\/10.1167\/iovs.16-20855","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"4029_CR24","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1167\/iovs.09-4493","volume":"52","author":"L Pelosini","year":"2011","unstructured":"Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J (2011) Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci 52(5):2741\u20132748. https:\/\/doi.org\/10.1167\/iovs.09-4493","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4029_CR25","doi-asserted-by":"publisher","first-page":"251584142095051","DOI":"10.1177\/2515841420950513","volume":"12","author":"A Markan","year":"2020","unstructured":"Markan A, Agarwal A, Arora A, Bazgain K, Rana V, Gupta V (2020) Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema. Ther Adv Ophthalmol 12:2515841420950513. https:\/\/doi.org\/10.1177\/2515841420950513","journal-title":"Ther Adv Ophthalmol"},{"issue":"2","key":"4029_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00592-019-01389-4","volume":"57","author":"M Cavalleri","year":"2020","unstructured":"Cavalleri M, Cicinelli MV, Parravano M et al (2020) Prognostic role of optical coherence tomography after switch to dexamethasone in diabetic macular edema. Acta Diabetol 57(2):163\u2013171. https:\/\/doi.org\/10.1007\/s00592-019-01389-4","journal-title":"Acta Diabetol"},{"issue":"2","key":"4029_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/jamaophthalmol.2017.6256","volume":"136","author":"R Das","year":"2018","unstructured":"Das R, Spence G, Hogg RE, Stevenson M, Chakravarthy U (2018) Disorganization of inner retina and outer retinal morphology in diabetic macular edema. JAMA Ophthalmol 136(2):202\u2013208. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.6256","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"4029_CR28","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/bjophthalmol-2016-308726","volume":"101","author":"P Iacono","year":"2017","unstructured":"Iacono P, Parodi MB, Scaramuzzi M, Bandello F (2017) Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant. Br J Ophthalmol 101(6):791\u2013795. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-308726","journal-title":"Br J Ophthalmol"},{"key":"4029_CR29","doi-asserted-by":"publisher","first-page":"39161","DOI":"10.1038\/srep39161","volume":"6","author":"Y Mori","year":"2016","unstructured":"Mori Y, Suzuma K, Uji A et al (2016) Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema. Sci Rep 6:39161. https:\/\/doi.org\/10.1038\/srep39161","journal-title":"Sci Rep"},{"issue":"7","key":"4029_CR30","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.18240\/ijo.2018.07.18","volume":"11","author":"JW Wang","year":"2018","unstructured":"Wang JW, Jie CH, Tao YJ et al (2018) Macular integrity assessment to determine the association between macular microstructure and functional parameters in diabetic macular edema. Int J Ophthalmol 11(7):1185\u20131191. https:\/\/doi.org\/10.18240\/ijo.2018.07.18","journal-title":"Int J Ophthalmol"},{"issue":"13","key":"4029_CR31","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.1167\/iovs.18-25611","volume":"59","author":"E Midena","year":"2018","unstructured":"Midena E, Pilotto E, Bini S (2018) Hyperreflective intraretinal foci as an OCT biomarker of retinal inflammation in diabetic macular edema. Invest Ophthalmol Vis Sci 59(13):5366. https:\/\/doi.org\/10.1167\/iovs.18-25611","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"4029_CR32","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s13300-017-0332-x","volume":"8","author":"I Chatziralli","year":"2017","unstructured":"Chatziralli I, Theodossiadis P, Parikakis E et al (2017) Dexamethasone intravitreal implant in diabetic macular edema: real-life data from a prospective study and predictive factors for visual outcome. Diabetes Ther 8(6):1393\u20131404. https:\/\/doi.org\/10.1007\/s13300-017-0332-x","journal-title":"Diabetes Ther"},{"key":"4029_CR33","doi-asserted-by":"publisher","first-page":"6710","DOI":"10.1167\/iovs.09-5064","volume":"51","author":"GG De\u00e1k","year":"2010","unstructured":"De\u00e1k GG, Bolz M, Ritter M et al (2010) A systematic correlation between morphology and functional alterations in diabetic macular edema. Invest Ophthalmol Vis Sci 51:6710\u20136714","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4029_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/aos.12153","volume":"91","author":"L Reznicek","year":"2013","unstructured":"Reznicek L, Cserhati S, Seidensticker F et al (2013) Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment. Acta Ophthalmol 91:529\u2013536","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"4029_CR35","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.ophtha.2015.02.036","volume":"122","author":"R Sophie","year":"2015","unstructured":"Sophie R, Lu N, Campochiaro PA (2015) Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology 122(7):1395\u20131401. https:\/\/doi.org\/10.1016\/j.ophtha.2015.02.036","journal-title":"Ophthalmology"},{"issue":"7","key":"4029_CR36","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.oret.2024.03.016","volume":"8","author":"H Takahashi","year":"2024","unstructured":"Takahashi H, Abu-Qamar O, Girgis JM, Call C, Ghide BH, Marmalidou A, Liu Y, Waheed NK (2024) OCT biomarkers and visual acuity in the treatment of diabetic macular edema. Ophthalmol Retina 8(7):725\u2013727. https:\/\/doi.org\/10.1016\/j.oret.2024.03.016","journal-title":"Ophthalmol Retina"},{"key":"4029_CR37","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.2147\/opth.S146019","volume":"11","author":"AN Kulikov","year":"2017","unstructured":"Kulikov AN, Sosnovskii SV, Berezin RD, Maltsev DS, Oskanov DH, Gribanov NA (2017) Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study. Clin Ophthalmol 11:1995\u20132002. https:\/\/doi.org\/10.2147\/opth.S146019","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"4029_CR38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00417-016-3562-0","volume":"255","author":"Y Wong","year":"2017","unstructured":"Wong Y, Steel DHW, Habib MS, Stubbing-Moore A, Bajwa D, Avery PJ (2017) Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 255(4):733\u2013742. https:\/\/doi.org\/10.1007\/s00417-016-3562-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"4029_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4274\/tjo.galenos.2019.91962","volume":"50","author":"S Eraslan","year":"2020","unstructured":"Eraslan S, Y\u0131ld\u0131r\u0131m \u00d6, Dursun \u00d6, Din\u00e7 E, Orekici Temel G (2020) Relationship between final visual acuity and optical coherence tomography findings in patients with diabetic macular edema undergoing anti-VEGF therapy. Turk J Ophthalmol 50(3):163\u2013168. https:\/\/doi.org\/10.4274\/tjo.galenos.2019.91962","journal-title":"Turk J Ophthalmol"},{"issue":"2","key":"4029_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/bjophthalmol-2017-310483","volume":"102","author":"BS Gerendas","year":"2018","unstructured":"Gerendas BS, Prager S, Deak G et al (2018) Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema. Br J Ophthalmol 102(2):195\u2013203. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310483","journal-title":"Br J Ophthalmol"},{"key":"4029_CR41","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JW Yau","year":"2012","unstructured":"Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556\u2013564","journal-title":"Diabetes Care"},{"key":"4029_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2337\/diacare.27.2007.S84","volume":"27","author":"DS Fong","year":"2004","unstructured":"Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, American Diabetes Association (2004) Retinopathy in diabetes. Diabetes Care 27:84\u201387","journal-title":"Diabetes Care"},{"issue":"9735","key":"4029_CR43","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY (2010) Diabetic retinopathy. Lancet 376(9735):124\u2013136. https:\/\/doi.org\/10.1016\/S0140-6736(09)62124-3","journal-title":"Lancet"},{"issue":"3","key":"4029_CR44","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/iae.00000000000007","volume":"36","author":"KH Seo","year":"2016","unstructured":"Seo KH, Yu SY, Kim M, Kwak HW (2016) Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns. Retina 36(3):588\u2013595. https:\/\/doi.org\/10.1097\/iae.00000000000007. ((In eng))","journal-title":"Retina"},{"issue":"10","key":"4029_CR45","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3928\/23258160-20161004-03","volume":"47","author":"Y Itoh","year":"2016","unstructured":"Itoh Y, Petkovsek D, Kaiser PK, Singh RP, Ehlers JP (2016) Optical coherence tomography features in diabetic macular edema and the impact on anti-VEGF response. Ophthalmic Surg Lasers Imaging Retina 47(10):908\u2013913. https:\/\/doi.org\/10.3928\/23258160-20161004-03","journal-title":"Ophthalmic Surg Lasers Imaging Retina"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04029-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04029-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04029-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:08:42Z","timestamp":1772780922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04029-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4029"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04029-3","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"146"}}